N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research

References

• WHO. Global information system on alcohol and health. 2015.
   Google Scholar
• Stoklosa TM, Morley KC, Volovets A, et al. Pharmacotherapy for alcohol use disorder in the context of liver disease. Current addiction reports.2018. doi:10.1007/s40429-018-0211-1
   Google Scholar
• Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. Journal of Hepatology. 2013;59(1):160–168.
   PubMed Web of Science ®Google Scholar
• Liang W, Chikritzhs T, Pascal R, et al. Mortality rate of alcoholic liver disease and risk of hospitalization for alcoholic liver cirrhosis, alcoholic hepatitis and alcoholic liver failure in Australia between 1993 and 2005. Intern Med J. 2011;41(1a):34–41.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Mirijello A, Leggio L, et al. Management of alcohol dependence in patients with liver disease. CNS Drugs. 2013;27(4):287–299.
   PubMed Web of Science ®Google Scholar
• Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130(2):124–134.
   PubMed Web of Science ®Google Scholar
• Khan A, Tansel A, White DL, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol. 2016;14(2):191–202.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Haber P, Warner R, Seth D, et al. Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol. 2003;18:1332–1344.
   PubMed Web of Science ®Google Scholar
• McDonough M, Crowley P. Naltrexone and liver disease. Aust Prescr. 2015;38:151.
   PubMed Web of Science ®Google Scholar
• Latour P, Biraben A, Polard E, et al. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?. Hum. 2004;19(3):193–203.
   Google Scholar
• Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18(5):1162–1167.
   PubMed Web of Science ®Google Scholar
• Pierce M, Sutterland A, Beraha E, et al. Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 28(7):795-806.
   Web of Science ®Google Scholar
• Morley KC, Baillie A, Fraser I, et al. Baclofen in the treatment of alcohol dependence with or without liver disease (BacALD): a multi-site, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry. 2018;212(6):362–369.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922.
   Web of Science ®Google Scholar
• Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016;26(12):1950–1959.
   PubMed Web of Science ®Google Scholar
• Jamshidi N, Morley KC, Cairns R, et al. The impact of off-label baclofen prescribing: misuse, overdose and calls to the poisons information centre. Alcohol and Alcoholism. Under review.
   Google Scholar
• Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631–1636.
   PubMed Web of Science ®Google Scholar
• Dore GM, Lo K, Juckes L, et al. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol and Alcoholism. 2011;46(6):714–720.
   PubMed Web of Science ®Google Scholar
• Pelissier F, de Haro L, Cardona F, et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008–2013. Clin Toxicol (Phila). 2017;55(4):275–284.
   PubMed Web of Science ®Google Scholar
• Whyte IM, Francis B, Dawson AH. Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. Curr Med Res Opin. 2007;23(10):2359–2368.
   PubMed Web of Science ®Google Scholar
• Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when? Multidiscip Respir Med. 2016;11:8.
   PubMed Web of Science ®Google Scholar
• Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265–269.
   PubMed Web of Science ®Google Scholar
• Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522–555.
   PubMed Web of Science ®Google Scholar
• Schmitt B, Vicenzi M, Garrel C, et al. ffects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol. 2015;6:198–205.
   PubMed Web of Science ®Google Scholar
• de Andrade K, Moura FA, dos Santos JM, et al. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. International Journal of Molecular Sciences. 2015;16:30269–30308..
   Google Scholar
• Zheng W, Zhang QE, Cai DB, et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018;137(5):391–400.
   PubMed Web of Science ®Google Scholar
• Duailibi MS, Cordeiro Q, Brietzke E, et al. N-acetylcysteine in the treatment of craving in substance use disorders:systematic review and meta-analysis. Am J Addict. 2017;26(7):660–666.
   PubMed Web of Science ®Google Scholar
• Hwa L, Besheer J, Kash T. Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective. F1000Res. 2017;6:298.
   PubMedGoogle Scholar
• Barker JM, Lench DH, Chandler LJ. Reversal of alcohol dependence-induced deficits in cue-guided behavior via mGluR2/3 signaling in mice. Psychopharmacology (Berl). 2016;233(2):235–242.
   PubMed Web of Science ®Google Scholar
• Adams CL, Short JL, Lawrence AJ. Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. Br J Pharmacol. 2010;159(3):534–542.
   PubMed Web of Science ®Google Scholar
• Sari Y, Sakai M, Weedman JM, et al. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Alcohol and Alcoholism. 2011;46(3):239–246.
   PubMed Web of Science ®Google Scholar
• Spencer S, Kalivas PW. Glutamate transport: a new bench to bedside mechanism for treating drug abuse. Int J Neuropsychopharmacol. 2017;20(10):797–812.
   PubMed Web of Science ®Google Scholar
• Bauer J, Pedersen A, Scherbaum N, et al. Craving in alcohol-dependent patients after detoxification is related to glutamatergic dysfunction in the nucleus accumbens and the anterior cingulate cortex. Neuropsychopharmacology. 2013;38(8):1401–1408.
   PubMed Web of Science ®Google Scholar
• Prisciandaro JJ, Schacht JP, Prescot AP, et al. Associations between recent heavy drinking and dorsal anterior cingulate n-acetylaspartate and glutamate concentrations in non-treatment-seeking individuals with alcohol dependence. Alcohol Clin Exp Res. 2016;40(3):491–496.
   PubMed Web of Science ®Google Scholar
• Cheng H, Kellar D, Lake A, et al. Effects of alcohol cues on MRS glutamate levels in the anterior cingulate. Alcohol and Alcoholism. 2018.
   Web of Science ®Google Scholar
• Umhau JC, Momenan R, Schwandt ML, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry. 2010;67(10):1069–1077.
   PubMedGoogle Scholar
• Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6(7):743–749.
   PubMed Web of Science ®Google Scholar
• Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry. 2010;67(1):81–84.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Veltman DJ, Nederveen A, et al. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology. 2012;37(9):2143–2152.
   PubMed Web of Science ®Google Scholar
• de Timary P, Stärkel P, Delzenne NM, et al. A role for the peripheral immune system in the development of alcohol use disorders? Neuropharmacology. 2017;122:148–160.
   PubMed Web of Science ®Google Scholar
• Neupane SP. Neuroimmune interface in the comorbidity between alcohol use disorder and major depression. Front Immunol. 2016;7:655.
   PubMed Web of Science ®Google Scholar
• Crews FT, Sarkar DK, Qin L, et al. Neuroimmune function and the consequences of alcohol exposure. Alcohol Res. 2015;37(2):331–41, 44–51.
   PubMed Web of Science ®Google Scholar
• Leclercq S, de Timary P, Delzenne NM, et al. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017;7(2):e1048.
   PubMedGoogle Scholar
• Fox HC, Milivojevic V, Angarita GA, et al. Peripheral immune system suppression in early abstinent alcohol-dependent individuals: links to stress and cue-related craving. J Psychopharmacol. 2017;31(7):883–892.
   PubMed Web of Science ®Google Scholar
• Milivojevic V, Ansell E, Simpson C, et al. Peripheral immune system adaptations and motivation for alcohol in non-dependent problem drinkers. Alcohol Clin Exp Res. 2017;41(3):585–595.
   PubMed Web of Science ®Google Scholar
• Hanak C, Benoit J, Fabry L, et al. Changes in pro-inflammatory markers in detoxifying chronic alcohol abusers, divided by lesch typology, reflect cognitive dysfunction. Alcohol and Alcoholism. 2017;52(5):529–534.
   PubMed Web of Science ®Google Scholar
• Kalk NJ, Guo Q, Owen D, et al. Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [(11)C]PBR28 PET study. Transl Psychiatry. 2017;7(1):e996.
   PubMedGoogle Scholar
• Hillmer AT, Sandiego CM, Hannestad J, et al. In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Mol Psychiatry. 2017;22(12):1759–1766.
   PubMed Web of Science ®Google Scholar
• Schneider R Jr., Bandiera S, Souza DG, et al. N-acetylcysteine prevents alcohol related neuroinflammation in rats. Neurochem Res. 2017;42(8):2135–2141.
   PubMed Web of Science ®Google Scholar
• Mocelin R, Marcon M, D’Ambros S, et al. Biochemical effects of N-acetylcysteine in zebrafish acutely exposed to ethanol. Neurochem Res. 2018;43(2):458–464.
   PubMed Web of Science ®Google Scholar
• Kawaratani H, Tsujimoto T, Douhara A, et al. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm. 2013;2013:495156.
   PubMed Web of Science ®Google Scholar
• Morry J, Ngamcherdtrakul W, Yantasee W. Oxidative stress in cancer and fibrosis: opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biol. 2017;11:240–253.
   PubMed Web of Science ®Google Scholar
• Sacco R, Eggenhoffner R, Giacomelli L. Glutathione in the treatment of liver diseases: insights from clinical practice. Minerva Gastroenterol Dietol. 2016;62(4):316–324.
   PubMed Web of Science ®Google Scholar
• Sutherland GT, Sheedy D, Kril JJ. Neuropathology of alcoholism. Handb Clin Neurol. 2014;125:603–615.
   PubMedGoogle Scholar
• Seiva FR, Amauchi JF, Rocha KK, et al. Alcoholism and alcohol abstinence: N-acetylcysteine to improve energy expenditure, myocardial oxidative stress, and energy metabolism in alcoholic heart disease. Alcohol. 2009;43(8):649–656.
   PubMed Web of Science ®Google Scholar
• AAH-NAC Study Group, Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365(19):1781–1789.
   PubMed Web of Science ®Google Scholar
• Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon. 2010;10(1):12–16.
   PubMed Web of Science ®Google Scholar
• Lebourgeois S, Gonzalez-Marin MC, Jeanblanc J, et al. Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration. Addict Biol. 2018;23(2):643–652.
   PubMed Web of Science ®Google Scholar
• Quintanilla ME, Rivera-Meza M, Berrios-Carcamo P, et al. The “first hit”: marked inhibition by N-Acetyl Cysteine of chronic ethanol intake but not of early ethanol intakeparallel effects on ethanol-induced saccharin motivation. Alcohol Clin Exp Res. 2016;40(5):1044–1051.
   PubMed Web of Science ®Google Scholar
• Schneider R Jr., Santos CF, Clarimundo V, et al. N-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats. Alcohol. 2015;49(3):259–263.
   PubMed Web of Science ®Google Scholar
• Reissner KJ, Gipson CD, Tran PK, et al. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addict Biol. 2015;20(2):316–323.
   PubMed Web of Science ®Google Scholar
• Squeglia LM, Tomko RL, Baker NL, et al. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018;185:17–22.
   PubMed Web of Science ®Google Scholar
• Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–812.
   PubMed Web of Science ®Google Scholar
• Back SE, McCauley JL, Korte KJ, et al. A double-blind, randomized, controlled pilot trial of N-Acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry. 2016;77(11):e1439–e46.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Dodd S Gama C, et al. Effects of n-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. Acta Neuropsychiatrica. 2009;21(5):239–245
   PubMed Web of Science ®Google Scholar
• McClure EA, Gipson CD, Malcolm RJ, et al. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014;28(2):95–106.
   PubMed Web of Science ®Google Scholar
• Schulte MHJ, Wiers RW, Boendermaker WJ, et al. The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and ecological momentary assessment. Addict Behav. 2017;79:24–31.
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry. 2007;164(7):1115–1117.
   PubMed Web of Science ®Google Scholar
• Mousavi SG, Sharbafchi MR, Salehi M, et al. The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. Arch Iran Med. 2015;18(1):28–33.
   PubMed Web of Science ®Google Scholar
• Gray KM, Sonne SC, McClure EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249–257.
   PubMed Web of Science ®Google Scholar
• Prado E, Maes M, Piccoli LG, et al. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep. 2015;20(5):215–222.
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, et al.. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res. 2011;17(4):211–216.
   PubMed Web of Science ®Google Scholar
• Schulte M, Goudriaan AE, Kaag AM, et al. The effect of N-acetylcysteine on brain glutamate and gamma-aminobutyric acid concentrations and on smoking cessation: A randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2017;31(10):1377–1379.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75(1):39–45.
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66(7):756–763.
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Redden SA, et al. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):490–496.
   PubMed Web of Science ®Google Scholar
• Huang X, Liu X, Yu Y. Depression and chronic liver diseases: are there shared underlying mechanisms? Front Mol Neurosci. 2017;10:134.
   PubMed Web of Science ®Google Scholar
• Ewusi-Mensah I, Saunders JB, Wodak AD, et al. Psychiatric morbidity in patients with alcoholic liver disease. Br Med J (Clin Res Ed). 1983;287(6403):1417–1419.
   PubMedGoogle Scholar
• Teesson M, Slade T, Mills K. Comorbidity in Australia: findings of the 2007 national survey of mental health and wellbeing. Aust N Z J Psychiatry. 2009;43(7):606–614.
   PubMed Web of Science ®Google Scholar
• Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol and Alcoholism. 2006;41(3):278–283.
   PubMed Web of Science ®Google Scholar
• Hirose A, Terauchi M, Akiyoshi M, et al. Depressive symptoms are associated with oxidative stress in middle-aged women: a cross-sectional study. Biopsychosoc Med. 2016;10:12.
   PubMed Web of Science ®Google Scholar
• Lopresti AL. Cognitive behaviour therapy and inflammation: A systematic review of its relationship and the potential implications for the treatment of depression. Aust N Z J Psychiatry. 2017;51(6):565–582.
   PubMed Web of Science ®Google Scholar
• Brundin L, Sellgren CM, Lim CK, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry. 2016;6(8):e865.
   PubMed Web of Science ®Google Scholar
• Hermens DF, Chitty KM, Lee RS, et al. Hippocampal glutamate is increased and associated with risky drinking in young adults with major depression. J Affect Disord. 2015;186:95–98.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75(6):628–636.
   PubMed Web of Science ®Google Scholar
• Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214–219.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468–475.
   PubMed Web of Science ®Google Scholar
• Waterdrinker A, Berk M, Venugopal K, et al. Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry. 2015;76(5):665.
   PubMed Web of Science ®Google Scholar
• Cullen KR, Klimes-Dougan B, Westlund Schreiner M, et al. N-acetylcysteine for nonsuicidal self-injurious behavior in adolescents: an open-label pilot study. J Child Adolesc Psychopharmacol. 2018;28(2):136–144.
   PubMed Web of Science ®Google Scholar
• Bernardin F, Maheut-Bosser A, Paille F. Cognitive impairments in alcohol-dependent subjects. Front Psychiatry. 2014;5:78.
   PubMed Web of Science ®Google Scholar
• Tarter RE, Alterman AI. Neuropsychological deficits in alcoholics: etiological considerations. J Stud Alcohol. 1984;45(1):1–9.
   PubMedGoogle Scholar
• Skvarc DR, Dean OM, Byrne LK, et al. The effect of N-acetylcysteine (NAC) on human cognition - A systematic review. Neurosci Biobehav Rev. 2017;78:44–56.
   PubMed Web of Science ®Google Scholar
• Conus P, Seidman LJ, Fournier M, et al. e. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophrenia Bulletin. 2018;44(2):317–327.
   PubMed Web of Science ®Google Scholar
• Levi Bolin B, Alcorn JL 3rd, Lile JA, et al. N-Acetylcysteine reduces cocaine-cue attentional bias and differentially alters cocaine self-administration based on dosing order. Drug Alcohol Depend. 2017;178:452–460.
   PubMed Web of Science ®Google Scholar
• Ma Y, Gao M, N-Acetylcysteine Protects LD. Mice from high fat diet-induced metabolic disorders. Pharm Res. 2016;33(8):2033–2042.
   PubMed Web of Science ®Google Scholar
• Simet SM, Pavlik JA, Sisson JH. Dietary antioxidants prevent alcohol-induced ciliary dysfunction. Alcohol. 2013;47(8):629–635.
   PubMed Web of Science ®Google Scholar
• Volkmer DL, Sears B, Lauing KL, et al. Antioxidant therapy attenuates deficient bone fracture repair associated with binge alcohol exposure. J Orthop Trauma. 2011;25(8):516–521.
   PubMed Web of Science ®Google Scholar
• Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150–159.
   PubMed Web of Science ®Google Scholar